BIMZELX Data Reveals Lasting HS Control, Urges Early Treatment

DENVER, CO – March 27, 2026 – New long-term data has unveiled a promising horizon for individuals battling hidradenitis suppurativa (HS), a chronic and often debilitating skin disease. At the American Academy of Dermatology (AAD) Annual Meeting, biopharmaceutical company UCB presented three-year findings for its drug BIMZELX® (bimekizumab-bkzx), showing it provides durable symptom control and significantly improves outcomes, particularly when treatment is initiated earlier in the disease course.

The data, derived from post hoc analyses of the pivotal BE HEARD clinical trials, suggests that the vast majority of patients with moderate-to-severe HS treated with BIMZELX can achieve sustained relief from painful flare-ups, a cornerstone of the disease's burden.

A New Horizon for a Debilitating Disease

Hidradenitis suppurativa is far more than a simple skin condition. It is a chronic, painful, and deeply disruptive inflammatory disease characterized by recurrent nodules, abscesses, and pus-discharging tunnels that form in areas like the armpits, groin, and buttocks. The disease, which affects about one percent of the population, typically begins in early adulthood and is marked by frequent, unpredictable flare-ups that inflict severe pain and can lead to scarring and a significantly diminished quality of life.

"Over eighty percent of people living with HS experience periodic worsening of symptoms, or flares, at least once a month, which can impose an enormous strain on their lives," said Dr. Steven Daveluy of Wayne State University School of Medicine, speaking on the findings.

The new data offers a powerful counter-narrative to this cycle of suffering. A post hoc analysis of 367 patients who completed three years in the BE HEARD extension study found that an impressive 86.1% remained free of acute symptom exacerbations at scheduled clinic visits. For patients, this translates to a potential long-term reprieve from the painful and unpredictable nature of HS, offering a level of stability that has long been elusive.

The Science of Early Intervention

Beyond demonstrating durable control, the new analyses illuminate a critical 'window of opportunity' for treatment. The data strongly suggests that the sooner patients begin treatment with BIMZELX, the better their long-term outcomes.

One analysis compared patients with a shorter disease duration (less than 2.4 years) and moderate baseline severity against those with a much longer disease history (over 10.7 years) and severe baseline disease. The results were stark. At the three-year mark, 74.1% of the early-treatment group achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) of 90, a high bar for clinical improvement. In contrast, only 51.5% of patients with longer, more severe disease history reached the same endpoint. This underscores a pivotal message for both patients and clinicians: timing matters.

"These data suggest improved outcomes for those who start treatment earlier and with lower baseline severity, reinforcing the window of opportunity in HS and underscoring the importance of earlier diagnosis and treatment," said Donatello Crocetta, Chief Medical Officer at UCB.

BIMZELX works by selectively inhibiting two key cytokines, or signaling proteins, that drive inflammation: interleukin 17A (IL-17A) and interleukin 17F (IL-17F). This dual-inhibition mechanism is distinct from other biologics that may only target IL-17A, which could contribute to its profound and durable efficacy. The findings presented at the AAD meeting, which consistently showed efficacy improvements across diverse patient subgroups regardless of age, sex, BMI, or disease severity, further strengthen the drug's clinical profile. While the company notes these findings are from post hoc analyses and should be interpreted with some caution, they provide compelling, hypothesis-generating evidence that could shape future research and clinical practice.

Reshaping the HS Treatment Landscape

The long-term BIMZELX data could catalyze a paradigm shift in how clinicians approach hidradenitis suppurativa. Historically, treatment has often followed a stepwise approach, with biologics reserved for patients who have failed multiple other therapies. However, the clear benefit of early intervention may encourage physicians to diagnose HS more proactively and consider highly effective treatments like BIMZELX sooner in the disease's progression.

This is particularly relevant in a competitive market that includes established TNF-alpha inhibitors and other IL-17 inhibitors. The demonstration of three-year flare control and the robust response in early-stage patients provides UCB with a powerful differentiator. The goal for HS management may increasingly shift from simply managing acute flares to achieving long-term, flare-free remission, fundamentally altering the trajectory of the disease for newly diagnosed patients.

UCB's Strategic Play in a Crowded Market

For UCB, the positive results are more than just a clinical victory; they represent a significant strategic milestone. BIMZELX is a cornerstone of the company's immunology portfolio, a 'pipeline in a product' with existing approvals for plaque psoriasis, psoriatic arthritis, and two forms of axial spondyloarthritis. Adding strong, long-term data in a challenging-to-treat condition like HS solidifies its potential as a multi-billion-dollar blockbuster.

The data strengthens UCB's position in the fiercely competitive autoimmune and inflammatory disease market. It not only provides clinicians with a compelling reason to prescribe BIMZELX but also provides payers with evidence of long-term value, which is critical for securing favorable market access and reimbursement.

With BIMZELX already approved for HS in Europe and under review by the U.S. Food and Drug Administration, this robust three-year data package arrives at a crucial time. It serves to bolster the drug's profile, support its adoption into clinical guidelines, and ultimately, offer a new standard of care and renewed hope for a patient community in desperate need of better, more durable treatment options.